Sources:
- McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15:1022-33.,Asghar U, Witkiewicz AZ, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130-46.,Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;4:392-401.,Beex L. Cycline-afhankelijke kinasen (CDK’s) als doelwit voor behandeling van gemetastaseerd mammacarcinoom. Oncotherapie 2017. https://medidact.com/oncologie/cycline-afhankelijke-kinasen-cdks-als-doelwit-behandeling-gemetastaseerd-mammacarcinoom/ ,Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus fulvestrant as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019; epub ahead of print, jan 10, 2019.,Turner NC, Slamon DJ, Ro I, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926-36.,Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541-7.,Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904-15.,Sledge GW Jr, Toi M, Neven P et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875-84.,Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.,Petrelli F, Ghidini A, Pedersini R, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat. 2019; epub ahead of print, jan 18, 2019.,Spring LM, Zangardi ML, Moy B and Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. The Oncologist. 2017;22:1039-48.,Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW. Fatal statin-induced rhabdomyolysis by possible interaction with palbociclib. Front Oncol. 2017;7:150.,Verma S, O’Shaughnessy J, Burris H, et al. Health-related quality of life of postmenopausal women with hormone receptor-poditive, human epidermal growth factor receptor-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat. 2018;170:535-45.,Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: Beyond cell cycle arrest. Trends in Biol. 2018;28:911-25.,www.oncoline.nl richtlijn borstkanker 1.01, revisie 2018.,Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology. 2018;29:1634-57.